Holen Sie sich die Stockscreener-App
74.77
4.37%
-3.42
Handel nachbörslich:
74.74
-0.03
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$78.19
Offen:
$78.82
24-Stunden-Volumen:
4.99M
Relative Volume:
0.94
Marktkapitalisierung:
$28.85B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
31.98
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
+2.75%
1M Leistung:
+23.36%
6M Leistung:
+10.67%
1J Leistung:
-11.85%
1-Tages-Spanne:
$74.64
$78.91
1-Wochen-Bereich:
$71.53
$78.91
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.77 | 30.17B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
89.17 | 158.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 120.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 105.25B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 72.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 50.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
TD Cowen Remains a Buy on Dexcom (DXCM) - The Globe and Mail
Dexcom Inc. stock (US2521311074): TD Cowen lifts target after strong Q1 momentum - AD HOC NEWS
TD Cowen raises DexCom stock price target to $95 on data - Investing.com
TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating - marketscreener.com
DexCom Inc (DXCM)'s Winning Formula: Financial Metrics and Compe - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
Pumps, patches and fixes at the ADA - BioWorld News
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc (DXCM) Stock Up 5.2% and Still Undervalued -- GF Scor - GuruFocus
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
Clinical Wins Boost Dexcom Growth Story In Type 2 DiabetesDexCom (NASDAQ:DXCM) - Benzinga
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes - Yahoo Finance Singapore
DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption - Quiver Quantitative
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom, Inc. (DXCM): Investor Outlook Reveals 13.92% Potential Upside In Continuous Glucose Monitoring Market - DirectorsTalk Interviews
DexCom (DXCM) Reports Positive Trial Results for Glucose Control in Type 2 Diabetes - GuruFocus
Is It Time To Reassess DexCom (DXCM) After Recent Glucose Monitoring Headlines? - Sahm
Dexcom G7 gave Type 2 adults 5 extra hours a day in range - Stock Titan
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin - The AI Journal
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study - Reuters
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum - Yahoo Finance
Dexcom (DXCM) EVP Jon Coleman sells 9,823 shares in planned trades - Stock Titan
Dexcom buys Nutrisense; Insulet rolls out patch pump update - MedTech Dive
Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating - marketscreener.com
Is DexCom Stock Underperforming the Dow? - Yahoo Finance
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DXCM (NASDAQ: DXCM) affiliate files Form 144; director sold 4,912 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 - StreetInsider
DexCom vs. Insulet: Growth Trajectories and Valuations for InvestorsNews and Statistics - IndexBox
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? - Yahoo Finance
Dexcom Reaffirms CGM Benefits for All People With Diabetes and C - GuruFocus
Dexcom to present diabetes study, launch new app, acquire Nutrisense By Investing.com - Investing.com Nigeria
Dexcom to present diabetes study, launch new app, acquire Nutrisense - Investing.com
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026 – Company AnnouncementFT.com - Financial Times
Elliott strikes Dexcom board settlement after taking stake - MSN
[144] DEXCOM INC SEC Filing - Stock Titan
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative? - Yahoo Finance
Dexcom Inc. stock (US2521311074): customer advisory report and recent trading in focus - AD HOC NEWS
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dexcom Inc-Aktie (DXCM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Coleman Jon | EVP, Chief Commercial Officer |
Jun 03 '26 |
Sale |
73.00 |
4,912 |
358,576 |
100,361 |
3.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):